Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Singh MP, Hoerste GMZ, Hu W, Mausberg AK, Cravens PD, Eagar T, Löber S, Klingenstein R, Gmeiner P, Korth C, Kieseier BC, Stueve O (2009)

Publication Type: Journal article

Publication year: 2009

Journal

Experimental Neurology Elsevier

Publisher: Elsevier

Book Volume: 215

Pages Range: 397-400

DOI: 10.1016/j.expneurol.2008.10.001

Abstract

Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

Authors with CRIS profile

Stefan Löber Lehrstuhl für Pharmazeutische Chemie Peter Gmeiner Lehrstuhl für Pharmazeutische Chemie

Involved external institutions

University of Texas Southwestern Medical Center (UT Southwestern) US United States (USA) (US) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) VA North Texas Health Care System US United States (USA) (US)

How to cite

APA:

Singh, M.P., Hoerste, G.M.Z., Hu, W., Mausberg, A.K., Cravens, P.D., Eagar, T.,... Stueve, O. (2009). Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Experimental Neurology, 215, 397-400. https://doi.org/10.1016/j.expneurol.2008.10.001

MLA:

Singh, Mahendra P., et al. "Quinpramine is a novel compound effective in ameliorating brain autoimmune disease." Experimental Neurology 215 (2009): 397-400.

BibTeX: Download